Abstract 2270
Background
Despite a population of over 180 million and over 115,950 new cases of cancer diagnosed every year, Nigeria has no dedicated medical oncologists (MO). Most oncology care is delivered through surgical (SO) and radiation oncologists (RO) who number less than 50 in the entire country. With the limited number of oncology professionals, cancer patients experience poor outcomes, with a less than 10% of 5-year cancer survival rate.
Methods
The participants were nominated by their institutions to attend the medical oncology training. Through the support of FSP and U.S. Embassy in Nigeria, MGM and TOC delivered 10-days of lectures based on ASCO, ESMO and NCCN guidelines in Abuja, Nigeria. Participants represented 15 Nigerian states, including 5 of the 6 ethnic and geographic regions. Mean correct scores of participants that completed both the pre- and post-course 25 question tests (composed by 2 of the authors TOC and MGM) were compared using GraphPad Prism 7.0a by Paired t-tests.
Results
Forty-four oncologists were identified of which 11 (25%) were females. Twenty-five (57%) completed both the pre- and post-tests and fully participated in the 10-day lecture series. 12 participates that completed the training were residents and 12 were attending physicians. One doctor did not identify as a resident or attending. Of the 25 that completed both tests, percentage of correct answers increased from 45% to 59% (2-sided p-value <0.0001). Benefits were seen both with attending doctors 45% to 59% (p = 0.0046) and resident doctors 45% to 59% (0.0007).
Conclusions
MO education coordinated by FSP and PPB improved MO knowledge in Nigeria regardless of participant background. Similar models may be employed across Sub-Saharan Africa. Reasons for lost participation need to be defined.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Project PinkBlue.
Funding
United States of America Department of State.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1291 - PD-L1 expression in uncommon EGFR-mutant non-small cell lung cancer and its response to immunotherapy
Presenter: Yun Fan
Session: Poster Display session 3
Resources:
Abstract
2171 - CCND1 Amplification Contributes to Immunosuppression in Head and Neck Squamous Cell Carcinoma and the Association with a Poor Response to Immune Checkpoint Inhibitors
Presenter: Chloe Huang
Session: Poster Display session 3
Resources:
Abstract
2624 - Efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer patients with sensitive genes mutation
Presenter: Hui-Juan Cui
Session: Poster Display session 3
Resources:
Abstract
3494 - Neutrophil to Lymphocyte Ratio (NLR) kinetics as predictors of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (NSCLC) patients treated with nivolumab (N).
Presenter: Audrey Simonaggio
Session: Poster Display session 3
Resources:
Abstract
3964 - Predictive markers of checkpoint inhibitor activity in adult metastatic solid tumours
Presenter: Alexandra Pender
Session: Poster Display session 3
Resources:
Abstract
3041 - Blood-based TMB (bTMB) correlates with tissue-based TMB (tTMB) in a multi-cancer Phase I IO Cohort
Presenter: Daniel Araujo
Session: Poster Display session 3
Resources:
Abstract
3910 - Analysis of Molecular Profile Complexities for Immunotherapy Decision Support
Presenter: Robert Dóczi
Session: Poster Display session 3
Resources:
Abstract
4836 - The Role of Tumor Neoantigens in the Differential Response to Immunotherapy (IO) in EGFR and BRAF Mutated Lung Cancers - Quantity or Quality?
Presenter: Katrina Case
Session: Poster Display session 3
Resources:
Abstract
1929 - Impact of previous corticosteroid (CS) exposure on efficacy of Programmed Cell Death-(Ligand) 1 blockade in patients with advanced Non-Small-Cell Lung Cancer (NSCLC): a single Center retrospective analysis
Presenter: Fabrizio Nelli
Session: Poster Display session 3
Resources:
Abstract
2601 - Comparison 18F-FDG-PET/CT criteria for prediction of therapy response and clinical outcome in patients with metastatic melanoma treated with Ipilimumab and PD-1 inhibitors
Presenter: Sabrina Vari
Session: Poster Display session 3
Resources:
Abstract